Lazabemide is a chemical compound primarily recognized for its role as a selective and reversible inhibitor of the enzyme monoamine oxidase B (MAO-B). This inhibition is significant in the context of neurochemistry, as it can influence the levels of neurotransmitters such as dopamine, which is particularly relevant in the treatment of neurodegenerative disorders like Parkinson's disease. Lazabemide is characterized by its ability to enhance dopaminergic activity without the irreversible effects associated with some other MAO inhibitors. The compound has a relatively low molecular weight and exhibits moderate lipophilicity, which may facilitate its penetration across the blood-brain barrier. Additionally, Lazabemide has been studied for its potential neuroprotective effects, making it a subject of interest in pharmacological research. Its safety profile and side effects are generally considered manageable, although further studies are necessary to fully understand its long-term implications in clinical use. Overall, Lazabemide represents a promising avenue in the pharmacotherapy of conditions associated with dopaminergic dysfunction.

Lazabemide

103878-84-8: Lazabemide is a chemical compound primarily recognized for its role as a selective and reversible inhibitor of the enzyme monoamine oxidase B (MAO-B). This inhibition is significant in the context of neurochemistry, as it can influence the levels of neurotransmitters such as dopamine, which is particularly relevant in the treatment of neurodegenerative disorders like Parkinson's disease. Lazabemide is characterized by its ability to enhance dopaminergic activity without the irreversible effects associated with some other MAO inhibitors. The compound has a relatively low molecular weight and exhibits moderate lipophilicity, which may facilitate its penetration across the blood-brain barrier. Additionally, Lazabemide has been studied for its potential neuroprotective effects, making it a subject of interest in pharmacological research. Its safety profile and side effects are generally considered manageable, although further studies are necessary to fully understand its long-term implications in clinical use. Overall, Lazabemide represents a promising avenue in the pharmacotherapy of conditions associated with dopaminergic dysfunction.

<p>Lazabemide (Ro 19-6327) is selective, reversible monoamine oxidase B (MAO-B) inhibitor (IC50 values are 0.03 and &gt; 100 μM for MAO-B and MAO-A respectively).</p>

CAS 103878-84-8

Lazabemide

Lazabemide

Ref: 7W-GP0341

LAZABEMIDE

Ref: TM-T5470